Aeluma, Inc. Q4 FY2026 earnings call

• Strategic Pivot to Commercialization: Management emphasized a shift from early-stage government R&D funding toward commercial revenue generation. While continuing to execute on aligned R&D programs, the focus is now on accelerating manufacturing and go-to-market strategies for AI Datacom products.
• Product Development (LINX & Quasar): Illuma is advancing two key product lines: the LINX series of high-speed photodetectors (S-Series for slow/wide interconnects and F-Series for fast/narrow 200G/400G lanes) and the Quasar family of MOCVD quantum dot lasers. These technologies utilize non-indium phosphide substrates to overcome supply chain bottlenecks associated with traditional indium phosphide materials.
• Supply Chain and Manufacturing Partnerships: A new agreement with Sumitomo Chemical Advanced Technologies strengthens wafer production capacity using existing MOCVD tools. Additionally, Illuma is procuring Axtron G10 MOCVD systems to expand in-house capabilities and support a multi-pronged approach leveraging various substrate sizes (150mm to 300mm).
• Key Hires and Team Expansion: The team grew from 14 employees at June 30, 2025, to over 30 currently. Key appointments include Dr. Brendan Moran (VP of Engineering), Jason Taylor (Senior Director of Program Management), and Dr. Pramit Parikh (Strategic Advisor), aimed at driving product development, program execution, and strategic partnerships.
• Government Relations and CHIPS Initiative: Illuma has entered definitive agreement negotiations for up to $30 million via the Department of Commerce CHIPS R&D office. This funding is viewed as a strategic equity investment rather than standard contract revenue, intended to accelerate commercialization efforts for AI infrastructure.

The company reported total revenue of $4.5 million for the full fiscal year 2026, which was near the high end of its prior guidance and approximately flat compared to fiscal 2025's $4.7 million. For the fourth quarter specifically, revenue was $582,000. The transcript does not provide a breakdown of financial performance by specific product segment or revenue contribution percentages; all revenue is attributed primarily to government contracts during this pre-commercialization phase.

• Fiscal 2027 Revenue Outlook: Management did not provide official quantitative guidance due to uncertainty in contract timing. They expect to recognize approximately $2.3 million of currently booked government contract revenue, with potential for an additional $2 million from opportunities under discussion.
• Commercial NRE Programs: Several multi-million dollar Non-Recurring Engineering (NRE) agreements are being negotiated with marquee commercial customers to accelerate qualification and commercialization.
• Capital Expenditures: Anticipated capital expenditures for fiscal 2027 are estimated between $10 million and $12 million, primarily for purchasing MOCVD reactors and test/validation tools to scale manufacturing capabilities.
• CHIPS Funding Status: The $30 million CHIPS R&D award is under negotiation; if finalized, it will likely be accounted for as an equity investment rather than revenue.

• Revenue Volatility and Timing: Revenue is heavily dependent on government contracts, which face timing uncertainties. The company is moving away from relying on these contracts for near-term growth, creating a transition risk as they pivot to commercial revenue.
• Execution Risk in Commercialization: The transition from R&D-focused operations to a commercial entity involves significant operational changes, including hiring, supply chain scaling, and customer engagement, which carries execution risk.
• Supply Chain Constraints: Traditional indium phosphide substrates are in short supply, expensive, and fragile. While Illuma’s non-indium phosphide technology aims to solve this, reliance on new manufacturing processes and partners introduces dependency risks.
• Market Adoption Uncertainty: Success depends on customers adopting new photonic components and transitioning architectures (e.g., to CPO/MPO). If market adoption slows or specifications change, commercialization timelines may extend.

Q: Daniel Yermackin asked if the shortfall in fiscal 2026 revenue, previously attributed to timing delays in government programs, would carry over into fiscal 2027. CFO Chris Stewart clarified that while there is about $2.3 million in booked government revenue for fiscal 2027 plus potential upside, the company is not providing official guidance due to the variability of contract terms and timing. He emphasized that current progress relies on executing signed projects rather than assuming delayed funds will materialize immediately.

A: CFO Chris Stewart responded that the company cannot give precise visibility beyond the $2.3 million in booked revenue because several contracts could significantly alter the range. He noted that while programs from prior years are continuing, the timing of revenue recognition remains uncertain, preventing formal guidance issuance for fiscal 2027.

Q: Richard Shannon inquired about the stage and urgency of negotiations for multiple NRE contracts, asking if they were exclusively in the AI DataCom market and how supply chain constraints were influencing these discussions. CEO Jonathan Klamkin confirmed the focus is almost entirely on AI DataCom in the near term. He explained that urgency is driven by forecasts showing current investments are insufficient for the 2028-2030 build-out, prompting customers to seek Illuma’s scalable non-indium phosphide solutions to fill future gaps.

A: CEO Jonathan Klamkin stated that customer interest in NRE programs is accelerating due to the realization that existing industry investments will not meet the massive demand projected for 2028 through 2030. He highlighted that Illuma’s ability to leverage different substrate sizes offers a strategic advantage in addressing both immediate needs and long-term scalability, driving strong engagement from top-tier manufacturers.

Q: Suji Da Silva asked whether the transition from pluggable transceivers to NPO and CPO architectures creates specific opportunities for Illuma and if this shift impacts demand for their photo detectors and lasers. CEO Jonathan Klamkin affirmed that new architectures create opportunities for custom components where off-the-shelf options are insufficient. He detailed that CPO and other advanced packaging methods require high-power lasers and specialized photodetector arrays that benefit from Illuma’s wafer-scale integration capabilities and reliability advantages.

A: CEO Jonathan Klamkin explained that the move to advanced packaging like CPO drives demand for custom photonics that do not exist on the shelf. He noted that Illuma’s non-indium phosphide platform allows for direct CMOS integration and advanced packaging, which is critical for CPO applications. Additionally, their quantum dot lasers offer isolator-free packaging and higher reliability, addressing key pain points for customers adopting these new data center architectures.